Sphenopalatine ganglion: block, radiofrequency ablation and neurostimulation – a systematic review.
Sphenopalatine ganglion is the largest collection of neurons in the calvarium outside of the brain. ACTUALLY, THE SPHENOPALATINE GANGLION COULD BE CONSIDERED A PART OF THE BRAIN AS IT IS ALL CRANIAL NERVES. Over the past century (SINCE 1908), it has been a target for interventional treatment of head and facial pain due to its ease of access. Block, radiofrequency ablation, and neurostimulation have all been applied to treat a myriad of painful syndromes. Despite the routine use of these interventions, the literature supporting their use has not been systematically summarized. This systematic review aims to collect and summarize the level of evidence supporting the use of sphenopalatine ganglion block, radiofrequency ablation and neurostimulation.
Medline, Google Scholar, and the Cochrane Central Register of Controlled Trials (CENTRAL) databases were reviewed for studies on sphenopalatine ganglion block, radiofrequency ablation and neurostimulation. Studies included in this review were compiled and analyzed for their treated medical conditions, study design, outcomes and procedural details. Studies were graded using Oxford Center for Evidence-Based Medicine for level of evidence. Based on the level of evidence, grades of recommendations are provided for each intervention and its associated medical conditions.
Eighty-three publications were included in this review, of which 60 were studies on sphenopalatine ganglion block, 15 were on radiofrequency ablation, and 8 were on neurostimulation. Of all the studies, 23 have evidence level above case series. Of the 23 studies, 19 were on sphenopalatine ganglion block, 1 study on radiofrequency ablation, and 3 studies on neurostimulation.
(THE MYOMONITOR PROVIDES STIMULATION TO THE SPHENOPALATINE GANGLION HAS BEEN USED FOR OVER 50 YEARS IN TREATING CHRONIC HEAD AND NECK PAIN AND TMJ DISORDERS BUT IT IS NOT MENTIONED IN ANY OF THESE PAPERS)
The rest of the available literature was case reports and case series. The strongest evidence lies in using sphenopalatine ganglion block, radiofrequency ablation and neurostimulation for cluster headache. Sphenopalatine ganglion block also has evidence in treating trigeminal neuralgia, migraines, reducing the needs of analgesics after endoscopic sinus surgery and reducing pain associated with nasal packing removal after nasal operations.
CLUSTER HEADACHES HAVE THE STRONGEST EVIDENCE BASED ON THE LITERATURE . THERE ARE MANY NEW STUDIES BEING DONE AND SOME WERE PUBLISHED AFTER THIS REVIEW WAS SUBMITTED FOR PUBLICATION. THERE ARE MANY CASE STUDIES AND CASE SERIES.
Overall, sphenopalatine ganglion is a promising target for treating cluster headache using blocks, radiofrequency ablation and neurostimulation. Sphenopalatine ganglion block also has some evidence supporting its use in a few other conditions. However, most of the controlled studies were small and without replications. Further controlled studies are warranted to replicate and expand on these previous findings.
THE SPHENOPALATINE GANGLION BLOCK IS EXTREMELY SAFE AND FREQUENTLY VERY SUCCESSFUL IT TREATING MANY CONDITIONS LEADING IT TO BE UTILIZED WITHOUT RANDOMIZED CONTROLLED STUDIES. IT HAS OVER 100 YEARS OF USE FOR MANY CONDITIONS.
IN 1986 A POPULAR BOOK “MIRACLES ON PARK AVENUE” DETAILED THE PRACTICE OF A NYC ENT DR MILTON REDER WHOSE ENTIRE PRACTICE WAS USING SPG BLOCKS TO TREAT A WIDE VARIETY OF CONDITIONS. I LEARNED ABOUT SPG BLOCKS IN 1986 WHEN A PATIENT BROUGHT ME A COPY OF THIS BOOK.
The online version of this article (10.1186/s10194-017-0826-y) contains supplementary material, which is available to authorized users.
The sphenopalatine ganglion (SPG) is also known as pterygopalatine ganglion, nasal ganglion or Meckel’s ganglion. It is the largest and most superior ganglion of sensory, sympathetic and parasympathetic nervous system. It has the largest collection of neurons in the calvarium outside of the brain. It is also the only ganglion having access to the outside environment through the nasal mucosa. SPG gives rise to greater and lesser palatine nerves, nasopalatine nerve, superior, inferior and posterior lateral nasal branches, as well as the pharyngeal branch of the maxillary nerve. There are also orbital branches reaching the lacrimal gland.
Because of its proximity to multiple important neuroanatomic structures in pain perception, SPG has been postulated to be involved in facial pain and headaches for over a century. For headache, SPG is thought to play a central role in the generation of trigeminal autonomic cephalalgia (TAC). TAC is a broad term that encompasses cluster headache, paroxysmal hemicrania, and short-lasting unilateral neuralgiform headache attack with conjunctival injection and tearing (SUNCT). It is typically distributed in the trigeminal distribution with ipsilateral cranial autonomic features. TAC is characterized by parasympathetic (lacrimation, rhinorrhea, nasal congestion and edema) activation and sympathetic dysfunction (ptosis and miosis). These clinical features can be explained by the activation of the sympathetic and parasympathetic pathways within SPG . The disruption of this pathway by SPG blockade is thought to be central to relieving the headache produced by TAC. For face and neck neuralgias, connections of SPG with facial nerve, lesser occipital nerve and cutaneous cervical nerves are thought to be the mechanism . Irritation of the SPG can also cause orbital, periorbital and mandibular symptoms through its connection with the ciliary and otic ganglions and reflex otalgia by its connection with the tympanic plexus. Connections of SPG with the vagus nerve may produce visceral symptoms in dysfunctional states . SPG may also play an important role in vasodilation to protect the brain against ischemia from stroke or migraine with aura. This mechanism is thought to be through the postganglionic parasympathetic fibers, which are connected to the vascular beds of the cerebral hemisphere . Because the upper cervical roots are connected to the superior cervical ganglion through the sympathetic trunk, which is connected to the deep petrosal nerve then to the SPG, SPG blockade is thought to be able to relieve pain from the head, face, neck and upper back . This is the rationale for using SPG block in treating any head, face, neck pain refractory to conventional treatment.
SPG BLOCKS ARE FREQUENTLY UTILIZED IN EMERGENCY DEPARTMENTS IN PATIENTS WHO HAVE FAILED TREATMENT FOR SEVERE HEADACHE, CLUSTER HEADACHE OR MIGRAINE, OFTEN WITH GREAT SUCCESS. THIS REVIEW AND OTHER CURRENT RESEARCH MAY MOVE THIS TREATMENT INTO A FIRST LINE TREATMENT IN ER DEPARTMENTS FOR CLUSTER HEADACHES AND MIGRAINES. TEACHING PATIENTS TO SELF ADMINISTER THESE BLOCKS MAY AVOID THE NECESSITY FOR MANY ER VISITS.
Through the inhibition of the sympathetic trunk, SPG block was also thought to be useful in treating generalized muscle pain including fibromyalgia and low back pain . WHILE THERE IS NOT GOOD PUBLISHED DATA ON THIS MANY PATIENTS REPORT SUCCESS. THIS VIDEO IS ONE SUCH FIBROMYALGIA PATIENT. (https://www.youtube.com/watch?v=A5xUFtuZe_Y)
For postdural puncture headache, the pain mechanism is thought to be secondary to cerebrospinal fluid leak that exceeds the production rate, causing traction on the meninges and parasympathetic mediated reflex vasodilatation of the meningeal vessels. SPG blockade is thought to work through blocking the parasympathetic flow to the cerebral vasculature, allowing the cerebral vessels to return to normal diameter, thus relieving the headache . ANEW ARTICLE PUBLISHED FEBRUARY 2, 2018 IS AT THIS LINK. https://www.ncbi.nlm.nih.gov/pubmed/29402441 IT CONCLUDED THAT “blocking with ropivacaine was a simple, safe and effective technique, with immediate and sustained pain relief for at least 12-24h.”
Although the mechanism by which pain is produced from SPG is not well-characterized, SPG has been the treatment target ranging from cluster headache to low back pain. Three main types of interventions are currently available: chemical nerve block/lysis, radiofrequency ablation and neurostimulation. Some of these interventions are commonly performed in interventional pain clinics for treatment of headache resistant to conservative measures. Despite their use, the level of evidence for using SPG interventions varies widely across a myriad of conditions. I AM STRONGLY OPPOSED TO CHEMICAL LYSIS AND/OR RADIOFREQUENCY ABLATION. I SUGGEST THAT ONCE OR TWICE DILY SELF-ADMINISTRATION MAY BE MORE SUCCESSFUL AND CARRY SIGNIFICANTLY LOWER RISK.
In this systematic review, we sought to systematically collect the evidence supporting the use of these SPG interventions in treating various painful conditions. We also summarized the level of evidence for each condition and intervention.
This systematic review applies the guidelines issued in the latest Preferred Reporting Items for Systematic Reviews and Meta-Analysis (Additional file 1: PRISMA).
The electronic databases of PubMed (https://www.ncbi.nlm.nih.gov/pubmed/), Cochrane Central Register of Controlled Trials (CENTRAL, www.cochranelibrary.com), Google Scholar (https://scholar.google.com/) were searched to identify relevant articles. Additionally, references within eligible papers were screened for additional articles.
Literature search strategy
The search was conducted in May 2017. The search strategy was based on the Population, Intervention, Comparator, Outcome (PICO) framework and was conducted to find studies on sphenopalatine ganglion block, radiofrequency ablation and neurostimulation. Population (P) was defined as patients suffering from any medical condition; intervention (I) was limited to sphenopalatine ganglion block, sphenopalatine radiofrequency ablation, and sphenopalatine ganglion neurostimulation; patients receiving interventions were compared (C) to preintervention status, patients without treatment or healthy controls; the outcome (O) needed to either qualitatively or quantitatively measure the reduction in disease severity with intervention. The complete entered search strategy in PubMed was: “(sphenopalatine) AND ganglion) AND block” for sphenopalatine ganglion block; “(sphenopalatine) AND ganglion) AND radiofrequency” for radiofrequency ablation; and (sphenopalatine AND ganglion AND neurostimulation) OR (sphenopalatine AND ganglion AND neuromodulation).
I WOULD HAVE LIKED THE SEARCH TO INCLUDE SPG BLOCKS, PTERGOPALATINE GANGLION, MECKEL’S GANGLION AND NASAL GANGLION. I HAVE NOT DONE THIS SEARCH AT THIS POINT TO LOOK FOR ANY MISSING REFERENCES.
Eligibility criteria and study selection
To be included in this review, studies had to meet the following criteria: 1. The study sample was human. 2. Interventions must be SPG block, SPG radiofrequency ablation or SPG neurostimulation. 3. Articles had to be written in English. 4. Full-Text articles had to be available. 5. Conference abstracts and reviews were excluded.
MANY VALUABLE STUDIES COULD HAVE BEEN EXCLUDED BUT THIS IS A VERY LOGICAL STEP FOR A PAPER OF THIS KIND.
Data items and collection
The following items were compiled in the evidence tables for SPG block (Table 2–-12):12): first author, year of publication, medical condition treated, approach, imaging modality, medication used for the procedure, number of cases, study design and outcome. For radiofrequency ablation, the following additional items were collected: radiofrequency ablation temperature, type of radiofrequency ablation, parameter used and how to identify the correct position of the radiofrequency cannula/probe. For neurostimulation, the following additional items were collected: type of stimulator, type of stimulation and how to identify the correct position.
THIS FIRST TABLE HAD A REFERENCE THAT LOOKED AT 2000 PATIENTS WITH REMOTE DYSFUNCTIONS USING COTTON TIPPED APPLICATORS. THE REMOTE DYSFUNCTIONS WERE ARRESTED. I WILL ATTEMPT TO FIND THIS ORIGINAL ARTICLE TO ADD MORE INFORMATION. THIS IS REFERENCE 73 IN THIS PAPER.
|Byrd et al. ||1930||“Remote dysfunctions”||Cotton tipped applicator, transnasal approach||None||50% butyn||Over 2000 cases||Case series||Remote dysfunctions were ARRESTED|
Risk of bias assessment
The quality of randomized-controlled studies was assessed using the 7-item criteria in Review Manager Software version 5.35 provided by the Cochrane Collaboration . The 7-item criteria contained: (1) random sequence generation; (2) allocation concealment; (3) blinding of participants and personnel; (4) blinding of outcome assessment; (5) incomplete outcome data; (6) selective reporting and (7) other bias.
Analysis of evidence and recommendations
Level of evidence was graded based on Oxford Center for Evidence-based Medicine (1a: Systematic review of randomized-controlled trials. 1b: Individual randomized-controlled trials with narrow confidence interval. 2a: Systematic review of homogenous cohort studies. 2b: Individual cohort studies and low quality randomized-controlled trial. 3a: Systematic review of homogenous case-control studies. 3b: Individual case-control study. 4. Case series and poor-quality cohort and case-control studies. 5. Expert opinion. Grade of recommendation: A: Consistent level 1 studies. B: Consistent level 2 or 3 studies or extrapolations from level 1 studies. C: Level 4 studies or extrapolations from level 2 or 3 studies. D: Level 5 evidence or troublingly inconsistent or inconclusive studies of any level. Risk of bias in individual studies and across studies were not systematically assessed as most studies included in this review were case reports and case series.
The result of the search process is provided in Fig. 1. 60 articles were included for SPG block, 15 articles for SPG radiofrequency ablation, and 8 articles for SPG neurostimulation.
THIS ARTICLE EXCLUDED 56 ARTICLES ON SPG BLOCKS, 19 ON RADIOFREQUENCY ABLATION AND 79 ON NEUROSTIMULATION.
The evidence levels and grades of recommendation for SPG block, radiofrequency ablation and neurostimulation are summarized in Table 1. Any study with evidence level above case series is included in Table Table2.2. Risk of bias of randomized-controlled studies is summarized in Fig. 2. Most randomized-controlled studies included in this review have adequate randomization and blinding of participants and personnel.
In the following sections, we will summarize the level of evidence and grades of recommendations by the type of SPG interventions and associated medical conditions.
Sphenopalatine ganglion block
Sixty articles were included for sphenopalatine ganglion block. Of the 60 studies, 11 were small randomized-controlled studies, and 1 was retrospective case-control study. The rest of the literature included case reports and case series. The type of blocking agent varied across studies, but they could be broadly put into three categories: cocaine, voltage-gated sodium channel blocker (local anesthetics), and a combination of voltage-gated sodium channel blocker and steroids. Voltage-gated sodium channel blocker is the most commonly used agent.
There were nine articles on chronic cluster headaches collected through our literature search (see Table 3). One was a small double-blind placebo-controlled study (level 2b), six were case series and two were case reports (level 4, see Table Table3).3). Costa et al.  reported a double-blind, placebo-controlled study using 15 cases of episodic and chronic cluster headaches. Cluster headache was induced with nitroglycerin, and SPG was treated with 10% solution of cocaine hydrochloride (1 ml, mean amount of application of 40-50 mg), 10% lidocaine (1 ml) or saline using a cotton swab previously immersed in these solutions. The cotton swab was placed in the region corresponding to the sphenopalatine fossa under anterior rhinoscopy. This was done in both the symptomatic and the non-symptomatic sides for 5 min. Patients treated with cocaine and lidocaine reported relief in 31.3 min in the cocaine group and 37 min for lidocaine group, compared to 59.3 min in the saline group. The side effect was mainly the unpleasant taste of lidocaine. This study was limited by its small number of participants, the acutely induced cluster headache from nitroglycerin, and its measure on only short-term outcome.
I CONSIDER SPG BLOCKS TO BE A FIRST LINE TREATMENT OF CLUSTER HEADACHES ALONG WITH OXYGEN.
SELF-ADMINISTERED SPG BLOCKS MAY BE THE BEST CLUSTER HEADACHE PROPHYLAXIS.
Other case reports/series using cocaine and local anesthetics as blocking agents generally reported good immediate outcomes for aborting acute cluster headache. One study using cocaine reported 10 out of 11 patients receiving 50-100% relief from spontaneous cluster headache , another study using lidocaine reported four out of five patients receiving relief from nitrate-induced cluster headache . Because of the short-term relief from cocaine and lidocaine, steroid has been tried to prolong the relief provided by SPG block. In one case series, combination of triamcinolone, bupivacaine, mepivacaine and epinephrine helped improve severity and frequency of cluster headaches in 11 out of 21 patients . The same cocktail helped 55% of the 15 treated patients in another case series .
I ROUTINELY TEACH PATIENTS TO SELF ADMINISTER SPG BLOCKS WITH LIDOCAINE AND OFTEN LEAVE THEM IN FOR MUCH LONGER PERIODS OF TIME. I UTILIZE COTTON-TIPPED NASAL CATHETERS THAT PROVIDE CONTINUAL CAPILLARY FEED OF ANESTHETIC. PATIENTS WILL INITIALLY UTILIZE IT TWICE DAILY AND TAPER DOWN ADMINISTRATION OVER TIME.
In summary, SPG block has moderate evidence in treating cluster headache. The overall grade of recommendation is B for SPG block on cluster headache. The strongest evidence lies in aborting nitroglycerin-induced cluster headache using local application of cocaine or lidocaine with cotton swab through the transnasal approach. The side effect was mainly the unpleasant taste of lidocaine. Addition of steroid may provide longer relief, but the evidence remains weak (Grade C recommendation).
There were four articles on SPG block for trigeminal neuralgia through our literature search. One was a randomized-controlled study (level 2b), two were case series and one case report (level 4, see Table 4). Kanai et al. performed a randomized-controlled study with 25 participants with refractory second-division trigeminal neuralgia . In this study, twenty-five patients with second-division trigeminal neuralgia were randomized to receive two sprays (0.2 ml) of either lidocaine 8% or saline placebo in the affected nostril using a metered-dose spray. The paroxysmal pain triggered by touching or moving face was assessed. Intranasal lidocaine 8% spray significantly decreased the paroxysmal pain for an average of 4.3 h. The side effects were limited to local irritation with burning, stinging or numbness of the nose and eye, and bitter taste and numbness of the throat.
THE BITTER TASTE IN THE THROAT IS LESS WHEN UTILIZING SLOWLY RELEASED LIDOCAINE THROUGH COTTON-TIPPED NASAL CATHETERS. I HAVE SEEN EXCELLENT RESULTS IN A SMALL NUMBER OF TRIGEMINAL NEURALGIA PATIENTS. SOMETIMES IT IS NECESSARY TO UTILIZE AFRIN NASAL SPRAY (OXYMETAZOLINE) TO OPEN PASSAGES OR 2% LIDOCAINE SPRAY TO INCREASE COMFORT. I NEVER UTILIZE CORTICOSTEROIDS FOR THE SPG BLOCKS
One case series  and one case report  reported immediate pain relief from nerve blocks with lidocaine and bupivacaine. One case series used a combination of dexamethasone and ropivacaine with the Tx360 applicator, which resulted in short-term pain relief . Multiple blocks over time seemed to provide longer pain relief but it was restricted to isolated cases.
In summary, the overall grade of recommendation is B for SPG block on trigeminal neuralgia. The strongest evidence lies in treating with 8% lidocaine nasal spray in the affected nostril.
I WILL ALWAYS ADMINISTER BILATERAL SPG BLOCKS AS THEY SEEM TO BE MORE EFFECTIVE. WHEN I HAVE AN EASY AND DIFFICULT NASAL PASSAGEWAY I WILL ALWAYS BEGIN WITH THE EASIER TO NEGOTIATE SIDE AND SOMETIMES SEE COMPLETE RELIEF FROM CONTRALATERAL BLOCK. THE PATIENT USUALLY FEELS “EVEN BETTER” AFTER IPSILATERAL BLOCK.
The analgesia is effective but temporary (4.3 h). It is well-tolerated with side effects limited to local irritations.
THE LONGER EXPOSURE AND MORE FREQUENT APPLICATIONS ARE, IN MY OPINION, KEY TO THE BEST RESULTS.
Addition of steroid and use of the Tx360 applicator may be useful but there has not been a controlled study.
There was one small double-blind, placebo-controlled study and one long-term follow-up of the same study (level 2b), two case series and one case report (level 4, see Table 5). Cady et al.  reported a randomized-controlled study using the Tx360 device and bupivacaine to acutely treat chronic migraines with repetitive SPG blockade. 38 subjects with chronic migraines were included in the final analysis. Participants received a series of 12 SPG blocks with either 0.3 cm3 of 0.5% bupivacaine or saline delivered with the Tx360® through each nostril, over a 6-week period (2 SPG blocks/week). SPG block was found to be effective in reducing the severity of migraines up to 24 h. However, repetitive blocks did not provide any statistically significant relief at 1-month or 6-month follow-ups . The most common side effects were mouth numbness, lacrimation, and bad taste, but there was no statistical difference in frequency of side effects between the bupivacaine and saline groups.
I BELIEVE STUDIES DONE WITH DAILY OR TWICE DAILY SELF-ADMINISTRATION OF SPG BLOCKS WOULD SHOW FAR SUPERIOR RESULTS, THE TX360 HAS BEEN USED TO SELF ADMINISTER SPG BLOCKS BY SOME PROVIDERS AND I HAVE TAUGHT PATIENTS TO SELF-ADMINISTER SPG BLOCKS WITH THE SPHENOCATH AS WELL THIS VIDEO IS A MIGRAINE PATIENT:
Given the positive randomized-controlled study, grade of recommendation is B for short term treatment of chronic migraines using 0.5% bupivacaine with the Tx360 device®. It should be noted that the effect is only present for 24 h. and it is not suitable for patients seeking relief greater than 24 h.
Postoperative pain of the head and face
There were six randomized-controlled studies, one case-control study and one case series falling under this category (Table 6).
BILATERAL (ACCIDENTAL) SPG BLOCKS ROUTINELY ARE DONE FOR ORAL-MAXILLOFACIAL SURGICAL PROCEDURES THAT REQUIRE ANESTHESIA TO THE MAXILLARY DIVISION OF THE TRIGEMINAL NERVE.
Six randomized-controlled studies examined the efficacy of SPG blockade in reducing the needs of analgesics after endoscopic sinus surgery (level 2b). One study by Cho et al.  did not show significant difference between SPG block and placebo, but five additional randomized-controlled studies showed significant reduction in the need of post-operative analgesics in the group treated with SPG block [18–22]. The five positive studies used 0.5% lidocaine with epinephrine , 1.5% lidocaine with epinephrine , 0.5% bupivacaine or 0.5% levobupivacaine , 2% lidocaine and 1% tetracaine . The SPG block was applied using injections, bilaterally through the transnasal or palatal approach. There was no difference in complications between the treatment and placebo group.
Hwang et al.  reported a case-control study to assess the efficacy of SPG block in reducing the pain associated with nasal packing removal after nasal operation (level 3b). 1% lidocaine was injected into the greater palatine canal ipsilaterally using infrazygomatic approach. Participants reported significantly lower pain on the side of the nose that received SPG block compared to the control side.
Robiony et al.  reported one case series (level 4) on the effectiveness of combined maxillary transcutaneous nerve block and SPG block in reducing postoperative pain for surgical correction of skeletal transverse discrepancy of the maxilla.
Given five positive double-blind placebo-controlled studies and one negative study, the grade of recommendation is B for SPG block in improving postoperative analgesia efficacy after endoscopic sinus surgery. Each study blocked SPG with injection of different local anesthetics using different approaches. In 5 studies, SPG block was consistently found to be effective in reducing the need of analgesics after endoscopic sinus surgery. A combination with maxillary transcutaneous nerve block may be also helpful but further systematic study is necessary to evaluate its efficacy. Grade of recommendation is also B for reducing pain associated with nasal packing removal after nasal surgery, using lidocaine injection through the infrazygomatic approach.
Head and neck cancer pain
Three case reports and series were found (level 4 evidence, Table 7). One study was SPG block and two on SPG neurolysis with phenol. The largest case series was by Varghese et al. , who reported 22 cases of successful treatment with 6% phenol used via nasal endoscopy, as a neurolytic sphenopalatine ganglion block, for pain caused by advanced head and neck cancer. The overall grade of recommendation is C for any of these painful conditions.
THERE IS AN EXCELLENT ARTICLE FROM INDIA ON SELF (HOME) ADMINISTRATION OF SPG BLOCKS FOR CANCER PAIN. I HAVE DISCUSSED THIS AND REPRINTED THE ARTICLE WITH MY COMMENTS.
A total of three case reports and series were found through our search process (level 4 evidence, Table 8). All three articles reported successful treatment of postherpetic neuralgia with SPG block using local anesthetics. One study reported successful treatment of postherpetic neuralgia involving the ophthalmic division of the trigeminal nerve, by SPG block under direct visualization through nasal endoscopy . Another article reported success in treating sinus arrest in postherpetic neuralgia by SPG block through trans-nasal approach utilizing cotton tipped applicators , and one study reported successful treatment of herpes zoster within a heterogeneous case series . The overall grade of recommendation is C.
I HAVE SEEN VERY GOOD RESULTS IN UTILIZING SPG BLOCKS WITH OTHER TREATMENTS DO ADDRESS MUSCULOSKELETAL PAIN. PLEASE SEE THE FOLLOWING VIDEO:
There were two negative randomized-controlled study on head, neck and shoulder myofascial pain. There were also a small case-control study on low back pain, a small randomized-controlled study on chronic muscle pain syndrome and two large case series in our literature search (Table 9).
Successful treatment of lumbosacral pain with SPG block was initially reported in two large case series in the 1940s [28, 29]. However, further randomized-controlled studies dismissed these findings. Scudds et al.  reported a randomized-controlled study applying SPG block (cotton-tipped pledgelets with 4% lidocaine) to 42 participants with fibromyalgia and 19 participants with myofascial pain syndrome. He reported no statistical difference between treatment and placebo group in pain intensity, headache frequency, sensitivity to pressure, anxiety, depression, and sleep quality. Janzen et al.  reported a similar randomized-controlled study by applying SPG block with lidocaine spray. Forty-two participants with fibromyalgia and 19 with myofascial pain syndrome were included in his study. He again found not difference between the treatment and placebo group. Ferrante et al.  reported a randomized-controlled study with 13 cases of head, neck and shoulder myofascial pain and 7 healthy controls. He also showed no significant effect with SPG block. On low back pain, Berger et al.  reported a case-control study with 21 patients randomized to cocaine, lidocaine and saline. He did not find significant differences in outcomes. Given the negative randomized-controlled studies, it is not recommended to use SPG block on musculoskeletal pain.
THIS VIDEO IS A FIBROMYALGIA PATIENT:
Postdural puncture headache
There were two case series and one case report (level 4) reporting successful treatment of postdural puncture headache (Table 10). No higher-level studies were available. Cohen et al.  reported the largest case series of 32 cases with postdural puncture headache. In the series, 69% of the patients treated with transnasal SPG block were saved from epidural blood patch. The overall grade of recommendation is C for SPG block on postdural puncture headache.
Other pain syndromes of the head and face
Pain syndromes involving the head and face not belonging to any category mentioned above are summarized in Table 11. There was a negative randomized-controlled study using Tx360 device treating acute anterior and global headache . There were also multiple case reports and series on the effectiveness of SPG in controlling various types of head and facial pain. Local anesthetics and steroids have been used for SPG block, while phenol and alcohol have been used for SPG neurolysis. They have been successfully used in Sluder’s neuralgia, sphenopalatine maxillary neuralgia, facial neuralgia, sympathetic neuralgia, post-traumatic atypical facial pain, atypical odontalgia, pain from midline granuloma, herpetic keratitis, hemifacial headache, paroxysmal hemicrania, nasal pain, hemicrania continua and trigeminal neuropathy. The largest case series was provided by Rodman et al. , documenting 147 patients with various types of nasal pain and headache. He reported that 81.3% of the patients had pain relief after receiving SPG block with a mixture of bupivacaine and triamcinolone. Schaffer et al.  reported a randomized placebo-controlled study using Tx360 device to treat acute anterior or global headache. A total of 93 participants were recruited in the study, but the study showed no statistical significance between the treatment and control groups. Because of the result, we do not recommend SPG block for anterior or global headache. The overall grade of recommendation is C for other types of head and facial pain, including Sluder’s neuralgia, sphenopalatine maxillary neuralgia, facial neuralgia, sympathetic neuralgia, post-traumatic atypical facial pain, atypical odontalgia, pain from midline granuloma, herpetic keratitis, hemifacial headache, paroxysmal hemicrania, nasal pain, hemicrania continua and trigeminal neuropathy.
SPG block has been used for a myriad of other conditions not involved in painful syndromes of the head and face. These conditions include seizures associated nasal pathology, arthritic pain and muscle spasm, intercostal neuritis, persistent hiccups, ureteral colic, dysmenorrhea, peripheral painful vascular spasm, complex regional pain syndrome and hypertension (Table 12). Most of these studies reported significant improvement, but none of them had evidence level above case series. There was one randomized-controlled study in assessing the efficacy of SPG block in treating nicotine addiction, but the result was negative . One small double-blind cross-over study examined whether SPG block reduces experimentally induced pain using submaximal effort tourniquet test, but the SPG block failed to make a difference in pain perception .
Overall, the grade of recommendation for any of these syndrome remains at C. SPG block is not recommended for nicotine addiction due to the negative randomized study.
Summary for SPG block
Grade of recommendation of using SPG block is B for cluster headache, second-division trigeminal neuralgia, migraine, reducing the pain associated with nasal packing removal after nasal operation and for reducing the needs of analgesics after endoscopic sinus surgery. Out of these conditions, SPG block has the best evidence in reducing the needs of analgesics after endoscopic sinus surgery, as there are six randomized-controlled studies. It should be noted that the recommendation for cluster headache, second-division trigeminal neuralgia and migraine are each based on one small study, and it is only meant for acute treatment. There is no positive controlled study warranting chronic treatment with SPG block. For other pain syndromes, grade of recommendations is C due to the lack of positive controlled studies. These syndromes include postdural puncture headache, sphenopalatine maxillary neuralgia, facial neuralgia, sympathetic neuralgia, post-traumatic atypical facial pain, atypical odontalgia, pain from midline granuloma, herpetic keratitis, hemifacial headache, paroxysmal hemicrania, nasal pain, hemicrania continua, trigeminal neuropathy, cancer pain, seizures associated nasal pathology, arthritic pain and muscle spasm, intercostal neuritis, persistent hiccups, ureteral colic, dysmenorrhea, peripheral painful vascular spasm, complex regional pain syndrome and hypertension. Use of SPG block for myofascial pain, including fibromyalgia and head, neck, shoulder myofascial pain and low back pain, is not recommended due to several negative randomized-controlled studies.
Fifteen studies were included on the topic of SPG radiofrequency ablation. One study was a small but positive prospective cohort study for cluster headaches, while the other 14 studies were case reports and case series. There were no controlled studies.
There was one prospective cohort study and eight case reports/series on the treatment of cluster headache. Three case reports were on pulsed radiofrequency and six on continuous radiofrequency ablation (Table 13). Narouze et al.  performed a prospective cohort study of 15 cases of chronic cluster headaches treated with radiofrequency ablation using infrazygomatic approach under fluoroscopy guidance. A total of 0.5 mL of lidocaine 2% was injected and 2 radiofrequency lesions were carried out at 80 °C for 60 s each. After the ablation, 0.5 mL of bupivacaine 0.5% and 5 mg of triamcinolone were injected. He reported statistically improved attack intensity, frequency and pain disability index up to 18 months (level 2b). As for side effects: 50% (7/15) reported temporary paresthesias in the upper gums and cheek that lasted for 3-6 weeks with complete resolution. In only one patient, a coin-like area of permanent anesthesia over the cheek persisted. Sanders et al.  reported the largest case series of 66 cluster headache patients treated with radiofrequency ablation after 12 to 70 months. He reported complete relief in 60.7% of patients with episodic cluster headache, and in 30% of patients with chronic cluster headache. Of the 66 treated patients, eight patients experienced temporary postoperative epistaxis and 11 patients exhibited cheek hematomas. A partial radiofrequency lesion of the maxillary nerve was inadvertently made in four patients. Nine patients complained of hypoesthesia of the palate, which disappeared in all patients within 3 months.
The grade of recommendation is B for treating cluster headache with radiofrequency ablation because of the positive cohort study.
Other head and facial pain
IROUTINELY TREAT A WIDE VARIETY OF TMJ AND OROFACIAL PAIN CONDITIONS UTILIZING SELF ADMINISTERED SPG BLOCKS:
There were Seven case reports/series on various head and facial pain other than cluster headaches (all level 4, Table 14). These included Sluder’s neuralgia, posttraumatic headache, chronic head and facial pain, atypical trigeminal neuralgia, atypical facial pain, chronic facial pain secondary to cavernous sinus meningioma, trigeminal neuralgia and SPG neuralgia due to herpes zoster. Akbas et al.  reported a 27-case series with various types of head and facial pain. In 35% of the cases, pain was completely relieved, while 42% had moderate relief and 23% had no relief with the SPG radiofrequency ablation. Because there were only case reports and case series available, the grade recommendation is C for any of these conditions.
Summary for SPG radiofrequency ablation
Grade of recommendation is B for applying SPG radiofrequency ablation to intractable cluster headache. The protocol used in the cohort study took infrazygomatic approach under fluoroscopy and two radiofrequency ablations were carried out at 80 °C for 60 s. However, there is not yet a randomized-controlled study to test its efficacy. Grade of recommendation is C for other head and facial pain, including Sluder’s neuralgia, posttraumatic headache, atypical trigeminal neuralgia, atypical facial pain, chronic facial pain secondary to cavernous sinus meningioma, trigeminal neuralgia and SPG neuralgia due to herpes zoster.
Sphenopalatine ganglion neurostimulation
Eight studies were included for SPG neurostimulation. There was one randomized-controlled study with two long-term follow-ups of the same study and five case report/case series on sphenopalatine ganglion neurostimulation (Table 15).
TYHE BIGGEST USERS OF SPG NEUROSTIMULATION ARE NEUROMUSCULAR DENTISTS WHO HAVE BEEN UTILIZING ULF-TENS TO STIMULATE THE SPHENOPALATINE GANGLION FOR OVER 50 YEARS WHILE STIMULATING THE SOMATO-SENSORY COMPONENTS OF THE TRIGEMINAL AND FACIAL NERVES
There was one randomized-controlled study with two long-term follow-ups of the same study, and two case reports/series on cluster headache. Schoenen et al.  reported a randomized-controlled trial using SPG neurostimulator for patients with refractory cluster headaches. Twenty-eight patients underwent SPG stimulator implantation and stimulations were applied at the onset of cluster headache. The study employed a protocol that randomly inserted a placebo when treatment was initiated by the patient for a cluster headache attack. Three settings were delivered in a randomized fashion (1:1:1): full stimulation (i.e. customized stimulation parameters established during the therapy titration period), sub-perception stimulation, and sham stimulation. A total of 566 cluster headaches were treated, and pain relief was achieved in 67.1% of patients receiving full stimulation compared to 7.4% receiving sham treatment (P < 0.0001). Pain relief using sub-perception stimulation was not significantly different from sham stimulation (P = 0.96). Acute rescue medication was used in 31% of cluster headache attacks in patients receiving full stimulation, compared to 77.4% treated with sham stimulation (P < 0.0001) and 78.4% with sub-perception stimulation (P < 0.0001). In terms of side effect, most patients (81%) experienced transient, mild to moderate loss of sensation within distinct maxillary nerve regions; 65% of events resolved within 3 months. Jurgens et al.  reported a cohort study from the subjects who volunteered to be followed for 24 months from the study by Schoenen et al. In this study, 61% of patients were either acute responder (>50% relief from moderate or greater pain) or frequency responder (>50% in attack frequency) at 24 months. Barloese et al.  analyzed participants who experienced remission from the same dataset. 30% of participants were found to have at least 1 episode of complete attack remission in the 24-month period. Ansarinia et al.  reported a case series of 6 patients. Out of the 18 attacks recorded, there were 11 attacks receiving complete relief from the stimulations, 3 getting partial relief and 4 without relief.
With the positive randomized-controlled trial, the grade of recommendation is B for using SPG neurostimulation on cluster headache. Given the positive effect from these studies, further trials are encouraged.
There was one case series of 11 cases on SPG neurostimulation in acutely treating intractable migraine headaches . In this study, 11 patients with a history of migraine headache for a mean of 20 years were studied. Spontaneous and induced migraine headaches were acutely treated with SPG neurostimulation. Out of the 11 treated, two patients were pain-free, three had some pain reduction, while five had no response. Because of the largely negative response, there is currently not enough evidence for treating intractable migraine with SPG neurostimulation.
Other head and facial pain
There was one case series and one case report on other types of head and facial pain. William et al.  reported a case series on idiopathic facial pain, supraorbital neuropathy, hemicrania continua, facial anesthesia dolorosa and occipital neuropathy. SPG neurostimulation was combined with trigeminal or peripheral stimulation. 80% of the patients reviewed reported sustained relief in facial pain. It is unclear whether SPG stimulation alone would provide the same relief in these cases. Elahi et al.  reported a single case of SPG neurostimulation for idiopathic facial pain with good success.
Given the sparse literature, the grade of recommendation is C for SPG neurostimulation in idiopathic facial pain and D for SPG stimulation combined with trigeminal/peripheral stimulation in supraorbital neuropathy, hemicrania continua, facial anesthesia dolorosa and occipital neuropathy.
Summary for SPG neurostimulation
Grade of recommendation is B for applying SPG neurostimulation to cluster headache and C for idiopathic facial pain. There may be a role of combined SPG and trigeminal or peripheral neurostimulation in isolated cases. Due to its invasive nature, SPG neurostimulation warrants further investigations with more high quality, large-scale studies.
Sphenopalatine ganglion block
Sphenopalatine ganglion block has been used for over a century. In 1908, Sluder first proposed that inflammation in the posterior ethmoid and sphenoid sinuses may be involved in unilateral facial pain associated with tearing, congestion and rhinorrhea. He also claimed to have successfully treated facial neuralgia, asthma, earache and lower-half headache. Over time, the term Sluder’s neuralgia has varied definitions across the medical literature. Its characteristics mostly resemble cluster headache AND TMJ DISORDERS and it has been suggested that the term Sluder’s neuralgia be discarded . However, an analysis suggested that cluster headache and Sluder’s neuralgia may be two different entities . This review kept Sluder’s neuralgia and cluster headaches as two distinct type of headaches because of the differences. Since Sluder’s first publication, SPG block has been reported to be used successfully in treating multiple pain syndromes, including cluster headaches, trigeminal neuralgia, migraine, postherpetic neuralgia and atypical facial pain. It was also used for treating intractable cancer pain of the head and face as well as facial pain management after endoscopic sinus surgery. However, for most pain syndromes the evidence for using SPG nerve block remains at case report and case series level. There were a few small yet positive randomized-controlled studies in nitroglycerin-induced cluster headache, second-division trigeminal neuralgia, migraine, reducing the pain associated with nasal packing removal after nasal operation and for reducing the needs of analgesics after endoscopic sinus surgery. It should be emphasized that the evidence for treating these conditions with SPG block is based on very few small studies. The exception lies in reducing the needs of analgesics after endoscopic sinus surgery, which is backed by five randomized-controlled studies. It should be also noted that long-term treatment may not be beneficial, as demonstrated by the chronic repetitive block study in migraine by Cady et al. . When SPG block is offered as a treatment option, patients should be informed of such caveats.
Several techniques exist for SPG blockade. Four types of applications exist: cotton-tip applicator, Tx360 device, nasal spray and needle injections. Three main types of approaches exist: transnasal, transoral and infrazygomatic approaches. Cotton-tip applicator, Tx360 device and nasal spray can only be applied through the transnasal approach. Needle injection, on the other hand, can be performed in any approach. Applied local anesthetics included lidocaine, bupivacaine, ropivacaine, levobupivacine, mepivacaine, novocaine, nupercaine, pontocaine, monocaine, tetracaine, and prilocaine, with varying concentrations, but lidocaine and bupivacaine were by far the most common. Other medications include cocaine, ethanol and phenol. Co-medications included epinephrine, triamcinolone and dexamethasone. Some studies used fluoroscopy or CT to guide needle placement. Unfortunately, there are no head-to-head trials comparing the efficacy among different blocking strategies. The recommendations made in this article are based on strategies used in the positive controlled studies.
SPG BLOCKS WITH TRANSNASAL COTTON-TIPPED NASAL CATHETERS ARE EASY TO SELF ADMINISTER AND IN MY EXPERIENCE ARE EXTREMELY EFFECTIVE AND EASY FOR PATIENTS TO LEARN THE PROCEDURE.
Side effects from SPG blockade is typically local. Potential side effects are numbness and stinging at the root of the nose and palate, numbness or lacrimation of ipsilateral eye, and bitter taste and numbness of the throat. With needle injection techniques, there is also the risk of bleeding, infection and epistaxis.
Sphenopalatine ganglion radiofrequency ablation
The use of radiofrequency on sphenopalatine ganglion was first reported by Salar et al.  for treating Sluder’s neuralgia. Since the first report, there were multiple case reports on using SPG radiofrequency ablation in treating head and facial pain. About half of the reports focused on treating cluster headaches, but it has also been successfully used on patients with post-traumatic headache, atypical trigeminal neuralgia and anesthesia dolorosa after cavernous meningioma surgery. However, most of the literature today remains at the case report and case series level. There was only one small prospective cohort study on the effectiveness of SPG radiofrequency ablation. Well-controlled studies are yet to be performed to confirm the validity of this therapeutic modality in treating headache and facial pain.
Compared to the short-lived effect of SPG block, SPG radiofrequency ablation tend to be long lasting. Narouze et al.  reported statistically improved attack intensity, frequency and pain disability index up to 18 months in patients who underwent SPG radiofrequency ablation. As a comparison, Costa et al.  only reported shorter cluster headache duration with SPG block, and Cady et al. reported only up to 24 h of relief in chronic migraine  while no difference was found at 1 and 6 months with repetitive SPG block .
Most radiofrequency ablation of SPG were carried out with the infrazygomatic approach. The most commonly used temperature is 80 °C for thermal ablation, and 42 °C for pulsed ablation. There is unfortunately no head-to-head comparison between the two types of ablations. All studies confirmed the position of RF cannula/probe by applying low voltage sensory stimulation (between 0.2-0.1 V) while patients felt paresthesia or tingling sensation at the root of the nose. The only study with evidence level above case series was a cohort study on patients with chronic cluster headache . In this positive study, the authors applied 2 rounds of thermal ablation at 80 °C for 60 s each. Pre- and post-ablation medications were also given (pre: 0.5 ml of 2% lidocaine; post: 0.5 ml of 0.5% bupivacaine and 5 mg of triamcinolone).
Based on the study by Narouze et al. , about 50% (7/15) reported temporary paresthesias in the upper gums and cheek that lasted for 3-6 weeks with complete resolution. Rare permanent small zone of hypoesthesia over the cheek could also happen. In the large case series by Sanders et al. , of the 66 treated patients, eight patients experienced temporary postoperative epistaxis and 11 patients exhibited cheek hematomas. A partial radiofrequency lesion of the maxillary nerve was inadvertently made in four patients. Nine patients complained of hypoesthesia of the palate, which disappeared in all patients within 3 months.
Sphenopalatine ganglion neurostimulation
Neurostimulation has emerged in recent years as a potential therapeutic modality for headaches and facial pain. Even though number of studies on SPG neurostimulation has not been abundant, the overall quality of the studies has been high. The study by Shoenen et al.  was the only randomized-controlled study in using SPG neurostimulation to treat chronic cluster headache. Despite the small number of participants, the effectiveness is demonstrated by the large effect size and highly significant P value. The two long-term follow-up articles continued to support the effectiveness of such intervention [42, 43]. These three studies combined is the strongest piece evidence to date, suggesting that SPG neurostimulation is effective in treating cluster headache. There were other isolated case reports on the successful application of SPG neurostimulation to other pain syndromes, but higher level of evidence is lacking.
Stimulation settings vary widely across study subjects, stimulator models and studies. In the controlled study by Schoenen et al. , the mean frequency was 120.4 ± 15.5 Hz, mean pulse width 389.7 ± 75.4 μs with mean intensity 1.6 ± 0.8 mA during full stimulation. These numbers are for references only, and the stimulation setting should be individualized based on responses.
In Schoenen’s controlled study , the most common acute side effects are sensory disturbances (81%), pain (38%), swelling (22%). Other side effects included tooth pain (16%), trismus (16%), headache (9%), dry eye (9%), and hematoma (9%). Across all 32 patients, five device- or procedure-related serious adverse events occurred. The most common serious adverse events are due to erroneous lead placements and lead migration to adjacent nerves.
There are several limitations in our review. Firstly, articles could have been missed because only Pubmed, CENTRAL and Google Scholar were used. Second, most of the studies included in this review were case studies and case reports. By nature of these kinds of studies, publication bias will be skewed toward positive outcomes. Thirdly, due to the paucity of controlled studies, meta-analysis could not be adequately performed to create a quantitative analysis. Despite these limitations, this study was the first to systematically summarize SPG interventions. As more controlled studies become available, meta-analysis will be possible and thus providing better level of evidence in this developing field.
SPG has been the target for treating pain syndrome in the head and face for over a hundred years. The strongest evidence lies in using SPG block, radiofrequency ablation and neurostimulation on cluster headache. Sphenopalatine ganglion block also has good evidence in treating trigeminal neuralgia, migraines, reducing the needs of analgesics after endoscopic sinus surgery and reducing pain associated with nasal packing removal after nasal operations. Large-scale, double-blinded, randomized-controlled studies are warranted in establishing these techniques in treating cluster headache and other head and facial pain.
No funding was received for this manuscript.
Availability of data and materials
|TAC||Trigeminal autonomic cephalalgia|
Additional file 1:(64K, doc)
PRISMA checklist. (DOC 64 kb)
KWDH designed the study, managed the literature searches and summaries of previous related work and wrote the first draft of the manuscript. RP and SK critically reviewed the study manuscript and provided revisions for intellectual content. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
The online version of this article (10.1186/s10194-017-0826-y) contains supplementary material, which is available to authorized users.
Kwo Wei David Ho, Email: [email protected].
Rene Przkora, Email: ude.lfu.tsena@arokzrPR.
Sanjeev Kumar, Email: ude.lfu.tsena@ramuKS.
(Articles from The Journal of Headache and Pain are provided here courtesy of Springer)